BioSpace News Archive

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ANAVEX®2-73

Pluristem Therapeutics Inc., a leading regenerative medicine company developing a platform of novel biological products, announced results from a market access comprehensive research study conducted by Marwood Group, a healthcare advisory firm, for the critical limb ischemia market in the U.S.

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at the BIO CEO & Investor Conference at 11:15 a.m. EST on Monday, February 10, in the Wilder Room at the New York Marriott Marquis

GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Epidiolex® (cannabidiol) oral solution, CV.

Globe Life Inc. (NYSE: GL) announced today that its Co-Chief Executive Officers Gary Coleman and Larry Hutchison will present Wednesday, February 12, 2020 at the Bank of America Insurance Conference in New York City.

Truvian Sciences (“Truvian”), a healthcare company at the intersection of diagnostics and consumer technology, today announced that Shane Bowen, Ph.D. has joined the company as Senior Vice President of Engineering

Students Treated for Dermatologic Conditions Can Apply for the Scholarship Through April 27, 2020

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the fourth quarter and full year ended December 31, 2019 after the market closes on February 25, 2020.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the upcoming presentation of EEG data from its Phase 2 study at the American Clinical Neurophysiology Society (ACNS) 2020 Annual Meeting in New Orleans, Louisiana on February 7, 2020.

Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious diseases and cancer, announces that it has finalized the acquisition of a novel Hepatitis B Virus (HBV) potential treatment or cure from Seraph Research Institute.